March 2024
By: Dennis Killian, PharmD, PhD, 340B ACE
In early 2024, CMS rolled out changes to 340B modifier requirements for Part B drugs. There are more changes coming in 2025.
Is your organization prepared? Last month, we shared three considerations on how to remain compliant with 340B Report subscribers.
Although compliance with Medicare Part B billing falls outside of a HRSA audit scope, it is important that all covered entities remain compliant with those guidelines. Pharmacy leaders and 340B coordinators are well positioned to identify any 340B-specific billing discrepancies and can assist with routine auditing after billing changes are implemented.
The updated CMS billing guidance, which went into effect January 1, 2024, requires all providers and suppliers billing Medicare Part B for status indicator “K” 340B drugs to use the “JG” or “TB” modifier.
Starting January 1, 2025, all 340B covered entities must transition to the “TB” modifier on 340B claims for separately payable Medicare Part B drugs and biologics. Covered entities also have the option for early transition to the “TB” modifier in CY24.
A complete list of drugs with status indicators is available on the CMS website under the most recent Addendum B file, which is updated each calendar quarter.
Additional information can be found in the following resource: Medicare 340B Billing Changes